The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review
DMD is associated with a substantial economic burden related to the formal disease management, as well as extensive informal care and indirect (productivity) costs shouldered by parents and other nonprofessional caregivers. Although relatively well-captured for a few countries, comprehensive cost data are lacking for many geographical settings. Our portfolio of costs of DMD will help inform assessments of burden of illness, health technology evaluations of new therapies, and data gap analyses for future research.
Authors
- Erik Landfeldt (ORCID: https://orcid.org/0000-0002-5758-7151)
- Alfred Peter Born
- Valerie Deroo
- Luca Bello
- Anne-Berit Ekström
- Silene Giusti
- Maria Åberg
Institutions
- University of Padua (IT)
- Sahlgrenska University Hospital (SE)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- IQVIA (United Kingdom) (GB)
- IQVIA (United States) (US)
- Kungälvs Sjukhus (SE)
- IQ Samhällsbyggnad (SE)
- Italfarmaco (Italy) (IT)
- University of Gothenburg (SE)
- Umeå University (SE)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1007/s40273-026-01610-7
- Primary Topic
- Musicians’ Health and Performance
- Type
- article
- Field-Weighted Citation Impact
- 0.00